A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the potential placental transfer of ocrelizumab in women with
clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally
approved indications] whose last dose of ocrelizumab was administered any time from 6 months
before the last menstrual period (LMP) through to the first trimester (up to gestational week
13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the
infant.